NCT01607905 is a Phase 1 clinical trial of Selinexor in Solid Tumor, sponsored by Karyopharm Therapeutics Inc.

Who is sponsoring NCT01607905?

NCT01607905 is sponsored by Karyopharm Therapeutics Inc.

What drugs are being tested in NCT01607905?

Interventions in NCT01607905: Selinexor, Acetaminophen.

What condition does NCT01607905 study?

NCT01607905 studies Solid Tumor.

Is NCT01607905 still recruiting?

NCT01607905 is currently completed. Last updated 26 January 2023.

Are results published for NCT01607905?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-01-26 · How we verify

NCT01607905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Completed Phase 1 Results posted Last updated 26 January 2023

What this trial tests

Phase 1 trial testing Selinexor in Solid Tumor in 192 participants. Completed in 15 March 2016.

Timeline

18 June 2012

Primary endpoint
15 March 2016

15 March 2016

Quick facts

Lead sponsor	Karyopharm Therapeutics Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	192
Start date	18 June 2012
Primary completion	15 March 2016
Estimated completion	15 March 2016
Sites	6 locations across Denmark, Canada, United States

Drugs / interventions tested

Selinexor — full drug profile →
Acetaminophen (Paracetamol) — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Karyopharm Therapeutics Inc — full company profile →

Who can join

18 and older, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Primary · From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) was defined as an AE that meets one or more of the mentioned criteria; is fatal, life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly/birth def

Participants with TEAEs

Group	Value	95% CI
Arm A (Colorectal Cancer)	59
Arm B (Gynecological Cancer)	20
Arm C (Squamous Cell Cancer)	21
Arm D (Castrate-resistant Prostate Cancer)	21
Arm E (Glioblastoma Multiforme)	6
Arm F (Melanoma)	15
Arm G (Other Solid Tumors)	46

Participants with TESAEs

Group	Value	95% CI
Arm A (Colorectal Cancer)	30
Arm B (Gynecological Cancer)	13
Arm C (Squamous Cell Cancer)	9
Arm D (Castrate-resistant Prostate Cancer)	8
Arm E (Glioblastoma Multiforme)	2
Arm F (Melanoma)	5
Arm G (Other Solid Tumors)	24

Number of Participants With Treatment-related Treatment-emergent Adverse Events Primary · From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE was defined as an adverse event with an onset that occurs after receiving study drug. A treatment-related AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product; the event had a causal relationship with the treatment or usage.

Participants with Treatment-related TEAEs

Group	Value	95% CI
Arm A (Colorectal Cancer)	59
Arm B (Gynecological Cancer)	19
Arm C (Squamous Cell Cancer)	20
Arm D (Castrate-resistant Prostate Cancer)	21
Arm E (Glioblastoma Multiforme)	6
Arm F (Melanoma)	14
Arm G (Other Solid Tumors)	45

Participants with Treatment-related TESAEs

Group	Value	95% CI
Arm A (Colorectal Cancer)	6
Arm B (Gynecological Cancer)	2
Arm C (Squamous Cell Cancer)	1
Arm D (Castrate-resistant Prostate Cancer)	4
Arm E (Glioblastoma Multiforme)	1
Arm F (Melanoma)	1
Arm G (Other Solid Tumors)	9

Number of Participants With Treatment-emergent Adverse Events (TEAEs) Greater Than or Equal to Grade 3, Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03 Primary · From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care

Group	Value	95% CI
Arm A (Colorectal Cancer)	50
Arm B (Gynecological Cancer)	17
Arm C (Squamous Cell Cancer)	16
Arm D (Castrate-resistant Prostate Cancer)	17
Arm E (Glioblastoma Multiforme)	4
Arm F (Melanoma)	11
Arm G (Other Solid Tumors)	35

Number of Participants Who Experienced Dose Limiting Toxicity (DLT) Primary · Cycle 1 only (28-day cycle)

Evaluation of DLTs was only conducted in participants who participated in the Dose-escalation Phase. A DLT was defined as any of the following, considered possibly related to drug administration, occurring in the first 28 days (or 21 days for participants on Schedule 8) at the target dose (ie, for Schedule 2 this meant the first 4 weeks after the 12 mg/m2 run-in week): Missed selinexor doses due to drug-related toxicities, discontinuation of a participant due to a toxicity that was at least possibly related to study drug before completing Cycle 1.

Group	Value	95% CI
Arm A (Colorectal Cancer)	1
Arm B (Gynecological Cancer)	0
Arm C (Squamous Cell Cancer)	0
Arm D (Castrate-resistant Prostate Cancer)	0
Arm E (Glioblastoma Multiforme)	0
Arm F (Melanoma)	1
Arm G (Other Solid Tumors)	2

Recommended Phase 2 Dose (RP2D) Primary · From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months)

The RP2D was the maximum tolerated dose (MTD) or less. MTD was defined as the next lower dose level below the one in which \>1 of 3 participants or ≥2 of 6 participants experienced DLT, provided that dose level was ≤25 percent (%) lower than the highest (intolerable) dose tested. If the projected MTD was \>25% lower than the highest dose tested, then an additional cohort of ≥3 participants was added at a dose that was intermediate between the intolerable dose and the next lower dose.

Group	Value	95% CI
Arms A to G: Overall Solid Tumor Malignancies	35

Maximum Observed Plasma Concentration (Cmax) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

Cmax was defined as maximum observed concentration, taken directly from the plasma concentration data.

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	30
Selinexor Dose: 6 mg/m^2	75	± 38.2
Selinexor Dose: 12 mg/m^2	149	± 32
Selinexor Dose: 16.8 mg/m^2	168
Selinexor Dose: 20 mg/m^2	220	± 44.5
Selinexor Dose: 23 mg/m^2	308	± 12.1
Selinexor Dose: 28 mg/m^2	293	± 58.3
Selinexor Dose: 30 mg/m^2	413	± 46.7
Selinexor Dose: 35 mg/m^2	349	± 25.4
Selinexor Dose: 39 mg/m^2	528	± 12.5
Selinexor Dose: 40 mg/m^2	442	± 63.6
Selinexor Dose: 45 mg/m^2	390	± 25.3

Time of Maximum Observed Concentration in Plasma (Tmax) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

Tmax was defined as time of first observation of Cmax, taken directly from the plasma concentration data.

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	1
Selinexor Dose: 6 mg/m^2	2.1	0.9 – 7.5
Selinexor Dose: 12 mg/m^2	2.0	1.0 – 7.7
Selinexor Dose: 16.8 mg/m^2	2.1
Selinexor Dose: 20 mg/m^2	2.3	2.0 – 7.5
Selinexor Dose: 23 mg/m^2	2.1	1.1 – 8.0
Selinexor Dose: 28 mg/m^2	3.1	0.5 – 7.6
Selinexor Dose: 30 mg/m^2	2.9	0.5 – 7.7
Selinexor Dose: 35 mg/m^2	3.8	2.0 – 7.8
Selinexor Dose: 39 mg/m^2	3.1	1.0 – 4.3
Selinexor Dose: 40 mg/m^2	3.9	2.1 – 4.2
Selinexor Dose: 45 mg/m^2	4.2	2.1 – 8.0

Area Under the Concentration Time Curve From the Time of Dosing to Time in Plasma (AUC0-t) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

AUC0-t was defined as area under the concentration-time curve from time zero to the last non-zero concentration.

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	333
Selinexor Dose: 6 mg/m^2	707	± 13.6
Selinexor Dose: 12 mg/m^2	1578	± 21.0
Selinexor Dose: 16.8 mg/m^2	1369
Selinexor Dose: 20 mg/m^2	2446	± 23.3
Selinexor Dose: 23 mg/m^2	3387	± 17.7
Selinexor Dose: 28 mg/m^2	3106	± 31
Selinexor Dose: 30 mg/m^2	3861	± 16.6
Selinexor Dose: 35 mg/m^2	3691	± 25.0
Selinexor Dose: 39 mg/m^2	4885	± 15.3
Selinexor Dose: 40 mg/m^2	5255	± 24.4
Selinexor Dose: 45 mg/m^2	4390	± 24.9

Area Under the Concentration Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

AUC0-inf was defined as area under the concentration-time curve from time zero to infinity (extrapolated). It was calculated as AUC0-t + Ct/kel, where: Ct = the last observed non-zero concentration and Kel = elimination rate constant.

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	355
Selinexor Dose: 6 mg/m^2	808	± 5.2
Selinexor Dose: 12 mg/m^2	1613	± 21.4
Selinexor Dose: 16.8 mg/m^2	1455
Selinexor Dose: 20 mg/m^2	2269	± 27.2
Selinexor Dose: 23 mg/m^2	3332	± 17.3
Selinexor Dose: 28 mg/m^2	3936
Selinexor Dose: 30 mg/m^2	3961	± 12.1
Selinexor Dose: 35 mg/m^2	4585	± 18.2
Selinexor Dose: 39 mg/m^2	5014	± 18.0
Selinexor Dose: 40 mg/m^2	5294	± 24.0
Selinexor Dose: 45 mg/m^2	3395

Elimination Half-Life (t1/2) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

t1/2 was defined as elimination half-life, it was calculated as ln(2)/kel, where In = natural logarithm and kel = elimination rate constant.

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	6.2
Selinexor Dose: 6 mg/m^2	5.6	4.8 – 6.4
Selinexor Dose: 12 mg/m^2	5.0	4.1 – 7.8
Selinexor Dose: 16.8 mg/m^2	5.7
Selinexor Dose: 20 mg/m^2	5.6	4.2 – 7.5
Selinexor Dose: 23 mg/m^2	5.8	5.7 – 6.4
Selinexor Dose: 28 mg/m^2	5.7
Selinexor Dose: 30 mg/m^2	6.5	4.1 – 7.9
Selinexor Dose: 35 mg/m^2	6.0	4.0 – 7.0
Selinexor Dose: 39 mg/m^2	5.9	3.5 – 6.2
Selinexor Dose: 40 mg/m^2	6.9	5.4 – 7.2
Selinexor Dose: 45 mg/m^2	7.3

Apparent Total Body Clearance (CL/F) of Selinexor Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

CL/F was calculated as Dose/AUC0-inf, uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

Group	Value	95% CI
Selinexor Dose: 3 mg/m^2	0.20
Selinexor Dose: 6 mg/m^2	0.18	± 7.9
Selinexor Dose: 12 mg/m^2	0.19	± 16
Selinexor Dose: 16.8 mg/m^2	0.20
Selinexor Dose: 20 mg/m^2	0.19	± 27
Selinexor Dose: 23 mg/m^2	0.19	± 26.1
Selinexor Dose: 28 mg/m^2	0.18
Selinexor Dose: 30 mg/m^2	0.17	± 16.8
Selinexor Dose: 35 mg/m^2	0.20	± 26.7
Selinexor Dose: 39 mg/m^2	0.20	± 12.5
Selinexor Dose: 40 mg/m^2	0.19	± 24.4
Selinexor Dose: 45 mg/m^2	0.27

Apparent Volume of Distribution of Selinexor (Vd/F) Secondary · Cycle1, Day1: Pre-dose, 30, 60, 120, 240, 480 minutes

Vd/F was calculated as Dose/(kel \* AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight (kilogram).

Group	Value	95% CI
Selinexor Dose: 3 Milligram Per Square Meter (mg/m2)	1.8
Selinexor Dose: 6 mg/m2	1.4	± 12.5
Selinexor Dose: 12 mg/m2	1.4	± 22.5
Selinexor Dose: 16.8 mg/m2	1.6
Selinexor Dose: 20 mg/m2	1.6	± 20.9
Selinexor Dose: 23 mg/m2	1.6	± 21.2
Selinexor Dose: 28 mg/m2	1.5
Selinexor Dose: 30 mg/m2	1.6	± 6.6
Selinexor Dose: 35 mg/m2	1.6	± 26.6
Selinexor Dose: 39 mg/m2	1.5	± 26.1
Selinexor Dose: 40 mg/m2	1.9	± 31.1
Selinexor Dose: 45 mg/m2	2.8

Adverse events — posted to ClinicalTrials.gov

Time frame: From start of study drug administration to 30 days after last dose of study treatment (maximum duration of 45 months). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm A (Colorectal Cancer)

Serious: 30/59 (51%)

Deaths: —

Arm B (Gynecological Cancer)

Serious: 13/20 (65%)

Deaths: —

Arm C (Squamous Cell Cancer)

Serious: 9/21 (43%)

Deaths: —

Arm D (Castrate-resistant Prostate Cancer)

Serious: 8/21 (38%)

Deaths: —

Arm E (Glioblastoma Multiforme)

Serious: 2/6 (33%)

Deaths: —

Arm F (Melanoma)

Serious: 5/15 (33%)

Deaths: —

Arm G (Other Solid Tumors)

Serious: 24/47 (51%)

Deaths: —

Serious adverse events (78 terms)

Reaction	System	Arm A (Colorectal Cancer)	Arm B (Gynecological Cancer)	Arm C (Squamous Cell Cancer)	Arm D (Castrate-resistant …	Arm E (Glioblastoma Multif…	Arm F (Melanoma)	Arm G (Other Solid Tumors)
Sepsis	Infections and infestations	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Hypotension	Vascular disorders	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Large intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—
Lung infection	Infections and infestations	—	—	—	—	—	—	—
Syncope	Nervous system disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Cataract	Eye disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Spinal cord compression	Nervous system disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Cardiac failure	Cardiac disorders	—	—	—	—	—	—	—
Large intestinal stenosis	Gastrointestinal disorders	—	—	—	—	—	—	—
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—
Death	General disorders	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—

Other adverse events (198 terms — click to expand)

Reaction	System	Arm A (Colorectal Cancer)	Arm B (Gynecological Cancer)	Arm C (Squamous Cell Cancer)	Arm D (Castrate-resistant …	Arm E (Glioblastoma Multif…	Arm F (Melanoma)	Arm G (Other Solid Tumors)
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—
Dysgeusia	Nervous system disorders	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypomagnesaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Vision blurred	Eye disorders	—	—	—	—	—	—	—
Dry mouth	Gastrointestinal disorders	—	—	—	—	—	—	—
Blood creatinine increased	Investigations	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—
Dyspepsia	Gastrointestinal disorders	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Hypocalcaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—
Lymphopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—
Chills	General disorders	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—
Muscular weakness	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—

Most-reported serious reactions: Sepsis, Nausea, Small intestinal obstruction, Back pain, Hypotension, Thrombocytopenia, Large intestinal obstruction, Vomiting.

Data from ClinicalTrials.gov NCT01607905 adverse events section.

Sponsor's own description

Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Regulated cell death (RCD) in cancer: key pathways and targeted therapies.
Peng F, Liao M, Qin R, Zhu S, et al · · 2022 · cited 586× · PMID 35963853 · DOI 10.1038/s41392-022-01110-y
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, et al · · 2016 · cited 199× · PMID 26926685 · DOI 10.1200/jco.2015.65.3949
XPO1-dependent nuclear export as a target for cancer therapy.
Azizian NG, Li Y. · · 2020 · cited 183× · PMID 32487143 · DOI 10.1186/s13045-020-00903-4
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J, Sanda T, Mansour MR, Kentsis A, et al · · 2013 · cited 159× · PMID 23373539 · DOI 10.1111/bjh.12231
Small molecule inhibitors targeting the cancers.
Liu GH, Chen T, Zhang X, Ma XL, et al · · 2022 · cited 127× · PMID 36254250 · DOI 10.1002/mco2.181
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
Gounder MM, Zer A, Tap WD, Salah S, et al · · 2016 · cited 124× · PMID 27458288 · DOI 10.1200/jco.2016.67.6346
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
Parikh K, Cang S, Sekhri A, Liu D. · · 2014 · cited 124× · PMID 25316614 · DOI 10.1186/s13045-014-0078-0
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.
Hing ZA, Fung HY, Ranganathan P, Mitchell S, et al · · 2016 · cited 116× · PMID 27323910 · DOI 10.1038/leu.2016.136

Verify or expand the search:

Other trials of Selinexor

Trials testing the same drug.

NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias · Phase 2 · not yet recruiting
NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07204041 — Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory · Phase 2 · active not recruiting
NCT06966154 — A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Se · Phase 1, PHASE2 · recruiting
NCT06900088 — Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients · Phase 2 · not yet recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Karyopharm Therapeutics Inc trials

Trials by the same sponsor.

NCT04854434 — A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previo · Phase 2 · terminated
NCT04768881 — Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma · Phase 2 · terminated
NCT04421378 — A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma · Phase 1, PHASE2 · terminated
NCT04355676 — Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COV · Phase 2 · withdrawn
NCT04349098 — Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01607905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karyopharm Therapeutics Inc
Last refreshed: 26 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01607905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01607905

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (78 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Selinexor

Other recruiting trials for Solid Tumor

Other Karyopharm Therapeutics Inc trials

Verify against primary sources